Chris A. Buhr - Concepedia

Author

Chris A. Buhr

Exelixis (United States)

Also Known As

C. A. BUHR, C. BUHR, C. Buhr, Chris A. Buhr, Chris Buhr

Publications

785

Citations

H-Index

Concepts

All Affiliations

Exelixis (United States)University of Pittsburgh Gilead Sciences (United States)

About

Chris A. Buhr is an author at Exelixis (United States) specializing in natural sciences, biochemistry, and chemical biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	8	8	631
2	Biochemistry	7	7	554
3	Engineering	5	5	445
4	Medicine	4	4	263
5	Biomolecular Engineering	3	3	137

Chris A. Buhr

Publications

783

Citations

H-Index

Page 1

	Year	Citations
Molecular recognition with convergent functional groups. VI. Synthetic and structural studies with a model receptor for nucleic acid components Ben Askew, Pablo Ballester, Chris A. Buhr, Journal of the American Chemical Society Molecular RecognitionMolecular CharacterizationMolecular SciencesEngineeringNucleic Acid Chemistry	1989	172
Molecular recognition: hydrogen bonding and stacking interactions stabilize a model for nucleic acid structure Julius Rebek, Ben Askew, Pablo Ballester, Journal of the American Chemical Society EngineeringAltmetric Attention ScoreMolecular BiologyChemical BiologyNucleic Acid Chemistry	1987	120
Molecular recognition with convergent functional groups. VII. Energetics of adenine binding with model receptors Kevin M. Williams, Ben Askew, Pablo Ballester, Journal of the American Chemical Society EngineeringAltmetric Attention ScoreMolecular BiologyChemical BiologyModel Receptors	1989	107
Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90 Joerg Bussenius, Charles M. Blazey, Naing Aay, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyProtein FunctionMedicineNatural SciencesMolecular Biology	2012	77
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway Peiwen Yu, Alexander Laird, Xiangnan Du, Molecular Cancer Therapeutics Pi3k/mtor Inhibitor Xl765Cancer BiologyPi3k PathwayTumor BiologyMolecular Pharmacology	2014	77
Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR) Craig S. Takeuchi, Byung Gyu Kim, Charles M. Blazey, Journal of Medicinal Chemistry Compound 28Drug TargetPharmacotherapyChemical BiologyPharmaceutical Chemistry	2013	65
Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza-2'- deoxyguanosine and 7-deaza-2'-deoxyadenosine Chris A. Buhr Nucleic Acids Research	1996	62
Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors James W. Leahy, Chris A. Buhr, Henry W. B. Johnson, Journal of Medicinal Chemistry Drug TargetPharmacotherapyChemical BiologyPharmaceutical ChemistryPre-clinical Pharmacology	2012	44
Molecular recognition: Watson-Crick, Hoogsteen, and bifurcated hydrogen bonding in a model for adenine recognition Julius Rebek, Ben Askew, Pablo Ballester, Journal of the American Chemical Society EngineeringChemical AnalysisAltmetric Attention ScoreMolecular BiologyChemical Biology	1987	30
Preparation of methyl 2,5-dioxohexanoate: a highly convenient reagent for the introduction of the 2-carbalkoxy-1,5-dialkylpyrrole nucleus Wayne J. Thompson, Chris A. Buhr The Journal of Organic Chemistry 2-Carbalkoxy-1,5-dialkylpyrrole NucleusMolecular SciencesEngineeringBiochemistryNatural Sciences	1983	16

Page 1